NCT02918123

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: Kang Stem Biotech Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Detailed description

This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis. Approximately 9\~18 subjects will be administrated FURESTEM-CD Inj. FURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.

Conditions

• Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	FURESTEM-CD Inj.	Patients will be treated FURESTEM-CD Inj. Subcutaneous injection

Timeline

• Start date: 2018-01-17
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2016-09-28
• Last updated: 2018-03-14

Locations

1 site across 1 country: South Korea